Drug interactions
Dalfampridine + Linagliptin-metformin
Severity: Moderate
Dalfampridine and Linagliptin-metformin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both metformin and dalfampridine are eliminated partly by renal OCT2-mediated secretion, so they could compete and raise each other's concentrations. Higher dalfampridine exposure raises seizure risk, particularly in patients with reduced renal function.
What this interaction means in plain words
Dalfampridine and Linagliptin-metformin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Dalfampridine belongs to Central Nervous System; Linagliptin-metformin belongs to Endocrine.
Why it happens
Competition at renal organic cation transporter 2 may reduce tubular secretion of both drugs.
What to do
Check renal function before and during co-therapy and monitor for dalfampridine toxicity such as seizures or metformin adverse effects. Avoid in patients with moderate or severe renal impairment.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dalfampridine and Linagliptin-metformin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Other interactions of Dalfampridine
Frequently asked questions
Can I take Dalfampridine with Linagliptin-metformin?
MediHelp rates the interaction as moderate. Dalfampridine and Linagliptin-metformin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Both metformin and dalfampridine are eliminated partly by renal OCT2-mediated secretion, so they could compete and raise each other's concentrations. Higher dalfampridine exposure raises seizure risk, particularly in patients with reduced renal function.
How serious is the interaction between Dalfampridine and Linagliptin-metformin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Check renal function before and during co-therapy and monitor for dalfampridine toxicity such as seizures or metformin adverse effects. Avoid in patients with moderate or severe renal impairment.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
